Does the media prefer ONC or BMY?

In the previous week, Bristol Myers Squibb had 32 more articles in the media than BeOne Medicines. MarketBeat recorded 40 mentions for Bristol Myers Squibb and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.38 beat Bristol Myers Squibb's score of 0.87 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 19 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, SNY or ONC?

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.10 $8.84B $1.91 22.39 BeOne Medicines $5.34B 7.12 $286.93M $5.68 61.01

Is SNY or ONC more profitable?

BeOne Medicines has a net margin of 10.70% compared to Sanofi's net margin of 8.66%. BeOne Medicines' return on equity of 14.23% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% BeOne Medicines 10.70% 14.23% 7.82%

Does the media favor SNY or ONC?

In the previous week, BeOne Medicines had 3 more articles in the media than Sanofi. MarketBeat recorded 8 mentions for BeOne Medicines and 5 mentions for Sanofi. BeOne Medicines' average media sentiment score of 1.38 beat Sanofi's score of 1.32 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ONC or GSK?

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 7.12 $286.93M $5.68 61.01 GSK $43.07B 2.26 $7.54B $3.20 15.04

Is ONC or GSK more profitable?

GSK has a net margin of 14.56% compared to BeOne Medicines' net margin of 10.70%. GSK's return on equity of 43.23% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 10.70% 14.23% 7.82% GSK 14.56% 43.23% 11.60%

Does the media refer more to ONC or GSK?

In the previous week, GSK had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 15 mentions for GSK and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.38 beat GSK's score of 0.60 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ONC or TAK?

BeOne Medicines currently has a consensus target price of $402.71, indicating a potential upside of 16.22%. Given BeOne Medicines' higher possible upside, equities research analysts plainly believe BeOne Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 3 Strong Buy rating(s) 3.00 Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media prefer ONC or TAK?

In the previous week, BeOne Medicines had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for BeOne Medicines and 2 mentions for Takeda Pharmaceutical. BeOne Medicines' average media sentiment score of 1.38 beat Takeda Pharmaceutical's score of 0.28 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TEVA or ONC?

In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.38 beat Teva Pharmaceutical Industries' score of 0.79 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 7 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BeOne Medicines (ONC) Competitors

$346.51 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$361.22 +14.72 (+4.25%)

As of 05:23 AM Eastern

Compare

ONC vs. BMY, SNY, GSK, TAK, and TEVA

Should you buy BeOne Medicines stock or one of its competitors? BeOne Medicines's main competitors and comparable companies include Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BeOne Medicines compare to Bristol Myers Squibb?

BeOne Medicines (NASDAQ:ONC) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

BeOne Medicines has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

In the previous week, Bristol Myers Squibb had 32 more articles in the media than BeOne Medicines. MarketBeat recorded 40 mentions for Bristol Myers Squibb and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.38 beat Bristol Myers Squibb's score of 0.87 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	19 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive

Bristol Myers Squibb has higher revenue and earnings than BeOne Medicines. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.12	$286.93M	$5.68	61.01
Bristol Myers Squibb	$48.19B	2.69	$7.05B	$4.54	13.99

BeOne Medicines currently has a consensus price target of $402.71, suggesting a potential upside of 16.22%. Bristol Myers Squibb has a consensus price target of $66.33, suggesting a potential upside of 4.42%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities research analysts plainly believe BeOne Medicines is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bristol Myers Squibb has a net margin of 18.87% compared to BeOne Medicines' net margin of 10.70%. Bristol Myers Squibb's return on equity of 66.90% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Bristol Myers Squibb	18.87%	66.90%	14.74%

Summary

BeOne Medicines beats Bristol Myers Squibb on 9 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Sanofi?

Sanofi (NASDAQ:SNY) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

BeOne Medicines has a net margin of 10.70% compared to Sanofi's net margin of 8.66%. BeOne Medicines' return on equity of 14.23% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
BeOne Medicines	10.70%	14.23%	7.82%

In the previous week, BeOne Medicines had 3 more articles in the media than Sanofi. MarketBeat recorded 8 mentions for BeOne Medicines and 5 mentions for Sanofi. BeOne Medicines' average media sentiment score of 1.38 beat Sanofi's score of 1.32 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$1.91	22.39
BeOne Medicines	$5.34B	7.12	$286.93M	$5.68	61.01

Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Sanofi presently has a consensus target price of $49.50, suggesting a potential upside of 15.74%. BeOne Medicines has a consensus target price of $402.71, suggesting a potential upside of 16.22%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.38
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

BeOne Medicines beats Sanofi on 14 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to GSK?

BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

GSK has a net margin of 14.56% compared to BeOne Medicines' net margin of 10.70%. GSK's return on equity of 43.23% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
GSK	14.56%	43.23%	11.60%

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.12	$286.93M	$5.68	61.01
GSK	$43.07B	2.26	$7.54B	$3.20	15.04

In the previous week, GSK had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 15 mentions for GSK and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.38 beat GSK's score of 0.60 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines currently has a consensus price target of $402.71, suggesting a potential upside of 16.22%. GSK has a consensus price target of $53.00, suggesting a potential upside of 10.11%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
GSK	2 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

BeOne Medicines has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Summary

BeOne Medicines beats GSK on 10 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

BeOne Medicines (NASDAQ:ONC) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BeOne Medicines has a net margin of 10.70% compared to Takeda Pharmaceutical's net margin of 3.80%. BeOne Medicines' return on equity of 14.23% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

BeOne Medicines currently has a consensus target price of $402.71, indicating a potential upside of 16.22%. Given BeOne Medicines' higher possible upside, equities research analysts plainly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, BeOne Medicines had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for BeOne Medicines and 2 mentions for Takeda Pharmaceutical. BeOne Medicines' average media sentiment score of 1.38 beat Takeda Pharmaceutical's score of 0.28 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

BeOne Medicines has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.12	$286.93M	$5.68	61.01
Takeda Pharmaceutical	$28.32B	2.07	-$1.01B	$0.34	53.72

Summary

BeOne Medicines beats Takeda Pharmaceutical on 15 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

BeOne Medicines has a net margin of 10.70% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
BeOne Medicines	10.70%	14.23%	7.82%

In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.38 beat Teva Pharmaceutical Industries' score of 0.79 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	7 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.50	$1.41B	$0.60	61.68
BeOne Medicines	$5.34B	7.12	$286.93M	$5.68	61.01

Teva Pharmaceutical Industries presently has a consensus price target of $43.10, suggesting a potential upside of 16.46%. BeOne Medicines has a consensus price target of $402.71, suggesting a potential upside of 16.22%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Summary

BeOne Medicines beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export

Metric	BeOne Medicines	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.04B	$12.45B	$7.15B	$12.84B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	61.01	799.77	275.25	25.35
Price / Sales	7.12	758.80	644.34	90.72
Price / Cash	88.65	14.86	28.42	34.96
Price / Book	8.71	10.45	10.36	6.21
Net Income	$286.93M	$2.85B	$3.50B	$358.54M
7 Day Performance	-3.28%	-3.57%	-3.31%	-2.39%
1 Month Performance	-0.28%	0.52%	-0.86%	-3.39%
1 Year Performance	6.84%	3.64%	23.55%	8.81%

BeOne Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONC BeOne Medicines	4.1914 of 5 stars	$346.51 flat	$402.71 +16.2%	+6.8%	$38.04B	$5.34B	61.01	12,000
BMY Bristol Myers Squibb	4.4807 of 5 stars	$63.46 -0.5%	$66.33 +4.5%	+37.4%	$129.57B	$48.19B	13.97	32,500	Trending News Analyst Revision
SNY Sanofi	3.5752 of 5 stars	$42.58 -0.3%	$49.50 +16.3%	-9.1%	$103.21B	$49.35B	22.29	74,846	Positive News
GSK GSK	3.9347 of 5 stars	$48.08 -0.1%	$53.00 +10.2%	+17.9%	$97.22B	$43.07B	15.03	66,841	Dividend Cut
TAK Takeda Pharmaceutical	1.618 of 5 stars	$18.26 +0.8%	N/A	+20.9%	$58.49B	$28.32B	53.69	47,000	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONC) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeOne Medicines (ONC) Competitors

ONC vs. BMY, SNY, GSK, TAK, and TEVA

How does BeOne Medicines compare to Bristol Myers Squibb?

Summary

How does BeOne Medicines compare to Sanofi?

Summary

How does BeOne Medicines compare to GSK?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeOne Medicines (ONC) Competitors

ONC vs. BMY, SNY, GSK, TAK, and TEVA

How does BeOne Medicines compare to Bristol Myers Squibb?

Which has more volatility & risk, ONC or BMY?

Does the media prefer ONC or BMY?

Which has better earnings & valuation, ONC or BMY?

Do analysts recommend ONC or BMY?

Do insiders & institutionals believe in ONC or BMY?

Is ONC or BMY more profitable?

Summary

How does BeOne Medicines compare to Sanofi?

Is SNY or ONC more profitable?

Does the media favor SNY or ONC?

Do institutionals & insiders hold more shares of SNY or ONC?

Which has preferable earnings and valuation, SNY or ONC?

Which has more volatility & risk, SNY or ONC?

Do analysts recommend SNY or ONC?

Summary

How does BeOne Medicines compare to GSK?

Is ONC or GSK more profitable?

Do insiders & institutionals hold more shares of ONC or GSK?

Which has higher valuation & earnings, ONC or GSK?

Does the media refer more to ONC or GSK?

Do analysts recommend ONC or GSK?

Which has more volatility & risk, ONC or GSK?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Do insiders & institutionals have more ownership in ONC or TAK?

Is ONC or TAK more profitable?

Do analysts recommend ONC or TAK?

Does the media prefer ONC or TAK?

Which has more volatility & risk, ONC or TAK?

Which has better earnings and valuation, ONC or TAK?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Is TEVA or ONC more profitable?

Does the media favor TEVA or ONC?

Which has preferable earnings & valuation, TEVA or ONC?

Do analysts rate TEVA or ONC?

Do insiders and institutionals believe in TEVA or ONC?

Which has more volatility & risk, TEVA or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools